Skip to main content
Caplight Logo









Nexosome Oncology

Nexosome Oncology

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://nexosome-oncology.com/

Last Round

Seed

Nov 1, 2021

Total Funding Raised

$4M

Company Overview

Nexosome Oncology is a biotechnology company that develops blood tests for early-stage cancer detection using extracellular vesicle proteomics and AI/ML biomarker discovery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Application

Keywords

liquid biopsyearly cancer detectionexosome-based diagnosticsbiomarker discoveryproteomics platformextracellular vesicle proteomicsEV proteomicscancer diagnosticsnon-invasive diagnosticsAI biomarker discoverypatient stratificationtherapy response monitoringELISA immunoassaysdiagnostic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nexosome Oncology Comparables

Compare Nexosome Oncology with similar companies based on industry and business-model similarity.

Nexosome Oncology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mursla Bio
78%
Mercy BioAnalytics
77%
Biological Dynamics, Inc.
71%

Nexosome Oncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedNov 1, 2021

Key People

Founding team and executive leadership

Todd Hembrough

Chief Executive Officer

Executive Team

Nexosome Oncology Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 1, 2021

    $4M round with participation from DigiTx Partners and Esplanade Ventures.

Nexosome Oncology Filings

Explore SEC and related filing metadata, where available.

Nexosome Oncology filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nexosome Oncology's valuation, stock price, and market status.

Is Nexosome Oncology a public or private company?

Nexosome Oncology is a private company.

What is the current stock price of Nexosome Oncology?

Nexosome Oncology is a private company with no public stock price. No recent secondary market data is available.

How much is Nexosome Oncology worth (valuation)?

Valuation information for Nexosome Oncology is not publicly available.

Can I buy Nexosome Oncology stock?

Nexosome Oncology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nexosome Oncology's last funding round?

Nexosome Oncology's most recent funding round was Seed on November 1, 2021.

Who are the main investors in Nexosome Oncology?

Key investors in Nexosome Oncology include DigiTx Partners, VisionTech Partners, Kentucky Science and Technology Corporation, Esplanade Ventures, XLerateHealth.

Will Nexosome Oncology IPO soon?

No public IPO plans have been announced for Nexosome Oncology.

How can I track Nexosome Oncology secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nexosome Oncology's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDurham, North Carolina
Employee Range5
Year Founded2021
Last FundingNov 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?